Is Ketamine Safe for Depression? Side Effects & Risks

Ketamine, when used at subanesthetic doses under medical supervision, is generally safe for treating depression, but it carries a distinct side-effect profile that sets it apart from traditional antidepressants. Most adverse effects are mild, transient, and dose-dependent, fading with repeated treatments.¹ That said, “safe” is doing a lot of heavy lifting in that sentence. The risk picture changes depending on whether you’re talking about a few supervised infusions or months of at-home oral lozenges, whether you’re 30 or 70, and whether you have certain medical conditions that make ketamine a poor fit.

What Is Actually FDA-Approved and What Is Not

This distinction matters for understanding the safety conversation. Only one form of ketamine has FDA approval for depression: esketamine, a nasal spray sold under the brand name Spravato. It is specifically approved for treatment-resistant depression and, separately, for major depressive disorder with suicidal thinking. “Regular” ketamine, administered intravenously or as oral lozenges, is used off-label for depression. Both approaches use subanesthetic doses, meaning far less than what an anesthesiologist would give you for surgery.²

The practical difference is that esketamine’s FDA approval came with a mandatory Risk Evaluation and Mitigation Strategy, or REMS. This means every dose must be given in a certified healthcare setting, and you stay for at least two hours of monitoring afterward.³ Off-label IV ketamine in clinics often follows similar monitoring protocols, but those safeguards aren’t legally required. At-home oral or sublingual ketamine prescribed through telehealth has the fewest guardrails of all, and that difference in oversight shapes the risk discussion considerably.

The Most Common Side Effects

The five side effects you’re most likely to experience during or shortly after a ketamine treatment are dissociation, anxiety, nausea, a temporary rise in blood pressure, and headache.¹ Most people describe these as uncomfortable but tolerable, and they tend to become less noticeable over the course of a treatment series.

Dissociation is the most talked-about effect. It can feel like being detached from your body, having a distorted sense of time, or experiencing dreamlike perceptual changes. In clinical studies, dissociative symptoms peak around 40 minutes after an IV infusion begins and resolve fairly quickly once the infusion ends.⁴ There has been a lot of interest in whether the dissociation itself is necessary for the antidepressant effect. In at least one controlled trial, the intensity of dissociation did not predict how much depression or suicidal thinking improved afterward, suggesting these are separate phenomena rather than two sides of the same coin.⁴

Psychotic-like symptoms, such as paranoid thoughts or perceptual disturbances beyond dissociation, occasionally occur but are rare and almost always brief. In a study of repeated IV ketamine infusions for treatment-resistant depression, researchers found that ketamine produced minimal positive psychotic symptoms, and the few instances of significant dissociation were transient.⁵

Blood Pressure and Heart Rate

Ketamine reliably bumps up blood pressure and heart rate. In a randomized, placebo-controlled trial, systolic and diastolic blood pressure and heart rate all increased significantly after ketamine infusion. The effect appeared about 10 minutes in and was no longer detectable by two hours after the start of the infusion. Critically, blood pressure did not reach hypertensive levels in the study participants.⁶

For most people, this temporary cardiovascular blip is clinically unimportant. But if you already have uncontrolled high blood pressure, a recent stroke, or certain heart conditions, the spike matters more. This is one of the primary reasons ketamine clinics check vital signs before, during, and after each session, and why people with significant cardiovascular disease are often screened out.

What About Addiction

Ketamine is a Schedule III controlled substance, and its recreational abuse history is well documented. So the question of whether medical ketamine for depression could lead to dependence is fair. A systematic review looking specifically at addiction risk during depression treatment found that the overwhelming majority of patients showed no signs of tolerance or dependence. Out of all patients studied, only four exhibited clear indicators of tolerance to ketamine’s antidepressant effect or dependence on the drug.⁷

The broader consensus in the literature frames the misuse risk as comparable to other commonly prescribed drugs that carry abuse potential, like stimulants for ADHD or benzodiazepines for anxiety. That does not mean the risk is zero. It means it calls for the same kind of careful prescribing: screening for substance-use history, using the lowest effective dose, monitoring for dose escalation or craving, and having a clear treatment plan with endpoints.⁸ Where things get murkier is in less supervised settings, particularly at-home prescribing models where patients have unsupervised access to the drug between appointments.

Organ-Level Concerns Over Time

Two organ systems come up in the longer-term safety conversation: the bladder and the liver.

Ketamine-induced cystitis is a well-known consequence of chronic, heavy recreational ketamine use. It involves bladder pain, reduced capacity, damage to the bladder lining, and in severe cases, narrowing of the ureters and kidney problems.⁹ The exact mechanism is still debated, but the prevailing theories point to ketamine metabolites in the urine triggering inflammatory damage to the bladder wall. The question for depression patients is whether the much lower doses used clinically pose the same risk. The evidence so far suggests that serious bladder problems are uncommon at clinical doses, but they’re not impossible, especially with long-term use. A systematic review of maintenance ketamine for treatment-resistant depression found that serious urinary problems seemed rare.¹⁰ Still, clinicians treating patients over many months tend to ask about urinary symptoms and sometimes order urine tests as a precaution.

Liver enzyme elevations have also been reported. In a case report, two patients developed substantial increases in liver enzymes within two days of restarting ketamine infusions after a gap of several months or more.¹¹ These cases are rare enough to warrant case reports rather than large cohort studies, which is a clue that clinically significant liver injury from subanesthetic ketamine is unusual. But it does underline why periodic blood work is a reasonable precaution for anyone on ongoing treatment.

Does Ketamine Damage the Brain

Animal research on ketamine and brain damage has a complicated history. Decades ago, studies in rats identified a type of brain lesion, known informally as Olney’s lesions, in animals given NMDA receptor-blocking drugs like ketamine. But the picture has gotten more nuanced. A 2021 study in rats found that ketamine at the doses and routes of administration used in that particular experiment did not produce these lesions, a finding the authors noted was at odds with earlier work. They attributed the discrepancy to differences in dosing, injection route, and rat strain.¹²

A 2025 review in the American Journal of Psychiatry pulled together both animal and human evidence. The takeaway: repeated or high-dose subanesthetic ketamine consistently produces excitotoxic neuronal damage and lasting cognitive problems in animals, particularly in very young (perinatal) animals. But infrequent administration at relatively low to moderate doses did not produce obvious brain damage in rat or primate models.¹³ That distinction between dose, frequency, and age of exposure is the crux of the safety question. The doses used for depression in adults are far lower and far less frequent than the exposures that cause damage in lab animals. But the review’s framing is cautious: we still don’t have long-term human brain imaging studies that definitively close the question.

On the cognitive front, the news for depression patients is more encouraging. A study looking at people with both PTSD and major depression who received a series of ketamine infusions found no worsening on any cognitive measures. In fact, working memory actually improved after the infusion series, likely reflecting the fact that treating severe depression tends to improve cognitive function on its own.¹⁴

Staying on Ketamine Long-Term

The initial course of ketamine for depression typically involves several infusions or nasal spray sessions over a few weeks. For people who respond, the question becomes: what happens when you stop? Relapse is common, which is why many patients end up on some form of maintenance treatment, spaced out over weeks or months. This raises the stakes on safety because the total lifetime exposure climbs.

A systematic review of maintenance ketamine treatment found that the approach was effective at sustaining antidepressant effects and that tachyphylaxis (needing increasingly higher doses), cognitive impairment, addiction, and serious bladder or kidney problems appeared uncommon.¹⁰ A more recent systematic review reported that adverse events during maintenance were generally mild to moderate, with about 7% of patients discontinuing because of side effects.¹⁵

A retrospective chart review of 85 outpatients paints a more granular picture. Nearly half discontinued during or right after the initial induction phase. Of those who transitioned to maintenance, the average dose was about 0.9 mg/kg. Only three patients in the entire cohort stopped specifically because of side effects.¹⁶ That suggests the main reason people stop is lack of sufficient response, not intolerance.

Drug Interactions Worth Knowing About

If you’re considering ketamine for depression, you’re likely already on other psychiatric medications. One interaction that stands out in the research is with benzodiazepines. Studies have repeatedly found that benzodiazepines shorten the duration of ketamine’s antidepressant effect.¹⁷ The likely explanation is pharmacological: benzodiazepines ramp up inhibitory brain signaling in a way that blunts the excitatory cascade ketamine triggers. This doesn’t necessarily make the combination dangerous, but it could make your ketamine treatment less effective. If you’re taking a benzodiazepine regularly, that’s something to discuss with your prescriber before starting ketamine.

Interactions with other antidepressants, mood stabilizers, and antipsychotics have been studied less thoroughly. Most ketamine treatment protocols don’t require patients to stop their existing medications, but the patchwork evidence on interactions means clinicians are often making judgment calls based on limited data.

Safety in Older Adults and Younger Populations

Most ketamine-for-depression research has been conducted in adults between 18 and 65. That leaves significant gaps at both ends of the age spectrum.¹⁸

For older adults, the cardiovascular bump is a bigger concern because hypertension and heart disease are more prevalent. There’s also evidence that older patients may respond less robustly to ketamine. A study comparing elderly and younger adults who received a series of six ketamine infusions found that antidepressant response trended lower in the older group, around 37% compared to about 58% in younger patients, and remission rates were lower as well.¹⁹ That matters for the risk-benefit calculation: if you’re older and facing both higher cardiovascular risk and a lower chance of response, the equation tilts differently than it does for a 35-year-old.

For adolescents, the data are even thinner. The animal literature showing that developing brains are more vulnerable to ketamine-related neurotoxicity adds a layer of caution.¹³ That doesn’t mean ketamine is categorically dangerous for teens, but it does mean there’s less evidence to lean on, and clinicians tend to be more conservative about recommending it for younger patients.

The At-Home Ketamine Question

The rapid expansion of telehealth ketamine services has created a natural experiment in what happens when you remove the in-clinic monitoring that most safety data were generated under. In a large real-world dataset from a telehealth-supported at-home ketamine program, adverse events were detected in roughly 3 to 5 percent of participants and were mostly neurological or psychiatric in nature. However, serious adverse events did occur: six patients experienced events classified as severe, including suicidal ideation, suicidal behavior, and psychosis, and most of those required hospitalization.²⁰

About 0.4% of patients had treatment discontinued because of adverse events, most commonly psychologically overwhelming experiences, anxiety, and agitation.²⁰ Those are small percentages in absolute terms, but they represent real psychiatric emergencies occurring outside a medical facility. This is one of the hottest debates in the field right now: at-home ketamine dramatically expands access for people who live far from specialized clinics or cannot afford in-person infusions, but it does so by removing the safeguards that make acute side effects manageable. Whether the tradeoff is acceptable depends heavily on how well the telehealth program screens patients, monitors them remotely, and has emergency protocols in place.

Who Should Probably Not Try Ketamine

Ketamine treatment protocols typically involve thorough psychiatric and medical assessments before the first dose. The screening process looks for conditions that would make ketamine either more dangerous or less likely to work. Common exclusion criteria across most protocols include:

Uncontrolled hypertension: because of the acute blood pressure increase
Active psychosis or a history of psychotic disorders: ketamine can temporarily worsen perceptual disturbances
Active substance-use disorder: given the drug’s abuse potential, current addiction complicates the risk-benefit picture
Unstable cardiovascular disease: the sympathomimetic effects add risk for people with recent heart attacks, aneurysms, or similar conditions
Pregnancy: human safety data during pregnancy are extremely limited

Beyond hard contraindications, the screening process ideally examines whether you have realistic expectations, a support system in place, and an existing treatment plan that ketamine would complement rather than replace. This is where the quality of care varies enormously: a well-run clinic does a multi-hour intake; some online prescribers do a brief questionnaire.

How Ketamine’s Side-Effect Profile Compares to Conventional Antidepressants

Traditional antidepressants like SSRIs and SNRIs have their own well-known side effects: sexual dysfunction, weight gain, emotional blunting, and discontinuation symptoms. These tend to be chronic, lasting as long as you take the medication and sometimes persisting after you stop. Ketamine’s side effects follow a different pattern. They’re largely acute, appearing during or shortly after each treatment and resolving within hours. You’re unlikely to gain weight from ketamine or experience the sexual side effects that lead many people to quit their SSRI.

On the other hand, you won’t have a dissociative episode or a blood pressure spike from an SSRI. The tradeoff is between chronic low-grade side effects that accumulate over months and acute, more dramatic side effects that resolve quickly. Neither profile is objectively “better”; it depends on what you find tolerable and what matters most in your daily life. For someone who has tried multiple antidepressants and found them ineffective or unbearable, the acute-but-transient side-effect pattern of ketamine can feel like a worthwhile trade, which is exactly the population ketamine treatment was designed for.

The one area where ketamine adds a category of risk that conventional antidepressants simply don’t carry is the potential for organ damage with prolonged use, specifically the bladder and liver concerns discussed above. SSRIs, for all their drawbacks, don’t erode your bladder lining. This makes ongoing monitoring a more active part of ketamine treatment than it is for someone on a standard antidepressant, and it’s one more reason the quality of your clinical team matters as much as the drug itself.